Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The user is experiencing increased hair shedding while using finasteride and RU58841, possibly due to changes in application methods. They are considering adding minoxidil and stemoxydine to their regimen to improve results and manage hair greasiness.

The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.

The conversation is about adjusting the dosage of topical Finasteride to avoid side effects like chest pain and breast swelling. The user is considering reducing the concentration to 0.1% or trying microdosing with 0.01-0.025% for lower systemic effects.

Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

RU58841 in glycerin may cause less irritation than in PG form, but its effectiveness might be reduced. Users discuss the potential trade-off between irritation and efficacy.

A dermatologist recommended using topical Dutasteride (15%) once a week, alongside oral Finasteride and Minoxidil, to improve hair strength and response. The user is seeking experiences or evidence on the effectiveness of this high-concentration regimen.

Concerns about using 0.3% topical finasteride due to potential side effects like decreased libido and gynecomastia. Suggestions include using less than 1ml or considering 1mg oral finasteride.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

The Sons combination spray for hair growth includes 0.15% topical finasteride, 5% minoxidil, and 0.015% tretinoin. Users discuss potential side effects like reduced libido and application methods affecting absorption.

The conversation discusses the effectiveness of finasteride and dutasteride for hair loss, with some users finding no improvement and experiencing side effects. It also mentions the use of RU58841 and topical minoxidil, highlighting that hair sensitivity to DHT varies among individuals.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

Some individuals experience hair loss despite using treatments like 2.5 mg dutasteride, finasteride, and minoxidil, suggesting sensitivity to DHT or other factors. Various treatments and lifestyle changes are discussed, but results vary, and some consider hair transplants or other solutions.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

The conversation is about the best concentration of Tretinoin to use with Minoxidil for hair growth, with suggestions ranging from 0.025% to 0.05%. Users discuss personal experiences and plans to adjust Tretinoin concentration for better results.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

User shares 1-year progress using 1mg Finasteride and 5% Minoxidil daily. Others praise results, discuss when improvements appeared, and mention shedding phase.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The user has been on dutasteride and oral minoxidil for a year with no progress and is considering increasing the dutasteride dose or adding RU58841. Other users suggest consulting a doctor, trying derma needling with topical minoxidil, and note that hair loss treatments can have varying effectiveness.

Start with 0.025% tretinoin to enhance minoxidil effectiveness, gradually increasing to 0.05% to avoid scalp irritation. Users experienced redness, inflammation, and dandruff when introducing tretinoin too quickly.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.